The purpose of this study was to determine the effect of dutasteride on quality of life of men with lower urinary tract symptoms associated with enlarged prostate or benign prostatic hyperplasia (BPH) as measured by symptom problem index (SPI), BPH-specific interference with activities (BSIA), BPH-specific psychological well-being (BPWB) and BPH-specific lifestyle adaptations (BSLA). Data were derived from three randomized, double-blind studies conducted in 4325 men treated with placebo or dutasteride (0.5 mg/day). Primary analyses included changes from baseline in mean SPI, BSIA, BPWB and BSLA scores. Men treated with dutasteride showed significant improvements in SPI, BSIA, BPWB and BSLA scores compared with placebo.
Introduction
Benign prostatic hyperplasia (BPH) is a condition that occurs commonly in aging men. 1 Many of these individuals develop lower urinary tract symptoms (LUTS) associated with prostatic enlargement and bladder outlet obstruction. Men with enlarged prostates often experience progressive worsening of clinical symptoms over time, including decreased maximum urinary flow rate (Q max ). 2 These individuals are also at greater risk for acute urinary retention (AUR) and BPH-related surgery.
As a result, BPH can have a tremendous impact on quality of life (QOL) in men who are bothered by their symptoms. 3 Although some men may remain relatively unbothered by severe symptoms, others with milder symptoms may be extremely bothered. The degree of symptom severity and associated bother can negatively impact a patient's general sense of well-being, including physical, social and psychological aspects of life. 3 In fact, patients with severe LUTS rate their health status as similar to or worse than that of patients with chronic obstructive pulmonary disease based on the SF-36 QOL questionnaire. 4, 5 Symptom severity clearly affects patients' health-related QOL, as patients with moderate-tosevere urinary symptoms report higher degrees of QOL impact in the areas of bother, interference, worry, sexual worry and sexual satisfaction, compared with patients reporting no or mild urinary symptoms. 6 Because the bother associated with BPH symptoms can negatively impact a patient's daily life, reduction of disease burden and subsequent improvement in the individual's healthrelated QOL should factor into treatment decisions for patients with enlarged prostates. 7 The 5a-reductase inhibitors (5ARIs) improve LUTS by shrinking prostate size. These agents prevent BPHrelated disease progression by inhibiting the ability of the 5a-reductase (5AR) enzyme to convert testosterone to dihydrotestosterone (DHT), the hormone responsible for prostate growth. In addition to improving symptoms by shrinking the prostate, 5ARIs decrease the risk of AUR and the need for BPH-related surgery. 8, 9 Finasteride, a selective inhibitor of the type II 5AR enzyme, reduces circulating DHT levels by approximately 70%. 8 Dutasteride is a dual inhibitor of both the type I and type II 5AR enzymes, which causes nearly complete suppression of DHT in both the serum and the prostate. 10 The purpose of the analyses reported herein was to determine the effect of dutasteride on QOL in men with LUTS associated with enlarged prostate or BPH.
Materials and methods
QOL data were obtained from three double-blind, placebo-controlled, parallel-group, phase III efficacy trials conducted over a 24-month period. Two of the three studies were conducted in the United States, and the third study recruited patients from 19 countries. All patients were experiencing LUTS associated with prostatic enlargement. All three studies had the same design, which consisted of a single-blind, placebo run-in followed by two years of double-blind treatment with either placebo or dutasteride (0.5 mg/day). Patients met the inclusion criteria if they were 50 years of age or older and had a clinical diagnosis of BPH; had a prostate volume measured by transrectal ultrasonography of 30 ml or greater; had an AUA-SI of 12 points or more; and had a maximal flow rate (Q max ) of 15 ml/s or less. In total, 4325 patients with LUTS caused by an enlarged prostate (X30 ml as measured by transrectal ultrasound) were randomized to dutasteride or placebo. The details of the methodology and results for the primary end points and safety analysis of the phase III studies were published previously. 9 QOL instruments used in the phase III studies included the symptom problem index (SPI), BPH-specific interference with activities (BSIA), BPH-specific psychological well-being (BPWB) and BPH-specific lifestyle adaptations (BSLA) questionnaires ( Table 1 ). The SPI is a seven-item questionnaire, which measures how troublesome urinary symptoms are for patients with BPH. The questions are scored on a five-point (0-4) scale, with higher scores indicating a greater degree of a perceived problem related to urinary symptoms. Questions in the SPI mirror the symptoms evaluated in the American Urological Association Symptom Index (AUA-SI) and attempt to quantify the actual degree of problems caused by each symptom. 11 The BSIA questionnaire measures the extent to which a number of activities (for example, playing outdoor sports) were compromised as a result of LUTS associated with an enlarged prostate. Each of the seven activities from the BSIA was evaluated using a five-point scale (0 ¼ none of the time; 4 ¼ all of the time). The SPI and BSIA questionnaires have been demonstrated to be valid and reliable QOL instruments. 12, 13 The BPWB questionnaire was developed specifically for these studies, as no established questionnaire at the time provided a comprehensive assessment of the emotional consequences of urinary symptoms. The BPWB questionnaire measures the extent to which urinary problems are embarrassing, frustrating or annoying. In addition to the instruments above, the BSLA was unique to the other questionnaires in this analysis because it was used only in the two US-based studies. The BSLA was also developed specifically for these studies and measured the frequency of a maximum of three coping behaviors, which were selected from a total of 19 items (Table 2) , based on urinary symptoms. Patients who experienced fewer symptoms following long-term treatment with dutasteride were expected to report a reduced frequency of coping behaviors when compared with baseline.
SPI scores were recorded at baseline and at months 12 and 24. BSIA and BPWB scores were recorded at baseline and during the treatment phase at months 1, 3, 6, 12, 18 and 24. For the BSLA questionnaire, patients were instructed to select a maximum of three adaptations (modified behaviors as a result of bothersome urinary symptoms), and to document the frequency of the adaptation at baseline. Patients were then instructed to re-evaluate the frequency of at least one adaptation at months 12 and 24.
A pooled, intent-to-treat (ITT) analysis from the three clinical trials was conducted. Patients in the ITT population were randomized to blinded treatment and received at least one dose of study medication. The results were analyzed using both last observation carried forward (LOCF) and at-visit analyses; the at-visit analyses are reported in this manuscript because they were not significantly different from the LOCF results. Treatment groups were compared in terms of the mean change from baseline in SPI, BSIA, BPWB and BSLA questionnaire scores using a general linear model, with Dutasteride improves quality of life measures MP O'Leary et al effects for baseline and treatment group. All questionnaires were correlated with the AUA-SI, and correlation coefficients were calculated. A significance level of 0.05 (based on a two-sided test) was considered to be statistically significant.
Results
Of the 4325 men randomized, 2951 (68%) completed the studies; reasons for withdrawal were previously published. 9 Baseline patient-demographic characteristics and pooled-baseline data are shown in Table 3 . Overall, baseline characteristics were similar in both treatment arms with respect to age and duration of BPH symptoms. Overall, statistically significant improvements in the SPI, BSIA, BPWB and BSLA questionnaires were seen at 24 months compared with baseline for men receiving dutasteride compared with placebo (Table 4) .
Symptom problem index
Baseline SPI scores were similar in the dutasteride and placebo groups (Table 4) . Across treatment groups, mean scores at baseline ranged from 1.2 for question 7 (straining to urinate) to 2.1 for question 3 (nocturia). Patients who received dutasteride therapy experienced a significant improvement in the mean change in SPI score when compared with patients who received placebo at months 12 and 24 (Po0.001) ( Table 4) . Dutasteride produced statistically significant changes in SPI score relative to placebo for all seven questions on the SPI at month 24 (Po0.001) ( Table 4 ). Men taking dutasteride reported the greatest improvement from baseline on question 2 (frequent urination), question 4 (interrupted flow) and question 6 (impaired urinary stream), a 0.5 change from baseline for all three (Po0.001). The largest treatment difference between groups (0.3) was for question 6 (impaired urinary stream), and the smallest treatment difference (0.1) was for question 3 (nocturia).
BPH-specific interference with activities
Baseline BSIA scores were similar for both treatment groups (Table 4) . Across treatment groups, mean scores at baseline ranged from 0.7 on question 6 (playing sports outdoors) to 1.5 on question 2 (drinking fluids before going to bed). Based on results from the BSIA questionnaire, patients in both treatment groups experienced similar mean changes in scores at months 1, 3 and 6. However, significant improvements from baseline in mean BSIA scores were observed at months 12, 18 and 24 for patients treated with dutasteride (Po0.001) compared with those on placebo. At month 24, significant changes in mean BSIA scores were reported by men in the dutasteride group for six of the seven questions, with the greatest effect on the first three questions. The largest treatment difference (mean change, À0.3) was on question 3 (how often have urinary problems interfered with driving for 2 h without stopping?). The smallest effect was seen on question 6 (how often have your urinary problems interfered with playing sports outdoors, such as golf?), which was not significantly different from placebo.
BPH-specific psychological well-being
At baseline, BPWB scores were similar for the dutasteride and placebo groups (Table 4) . Similar improvements in BPWB scores during visits at months 1, 3 and 6 were seen in patients in both treatment groups. Statistically significant improvements from baseline in BPWB scores were seen at months 12 (À1.4 vs À0.8), 18 (À1.5 vs À0.9) and 24 (À1.4 vs À0.6) for patients in the dutasteride group compared with those taking placebo, respectively (Po0.001). In addition, dutasteride produced significant reductions in BPWB scores from baseline for each individual question when compared with placebo at 12 and 24 months. The greatest effect was on question 5 
Dutasteride improves quality of life measures MP O'Leary et al
(during the past month, how much of the time have you wished your urinary problems could be improved?) in both treatment groups.
BPH-specific lifestyle adaptations
At least one adaptation was reported on the BSLA questionnaire by 86.7% of patients who participated in the two US-based studies. At baseline, the most commonly reported adaptation was urinating before leaving home (67%) ( Table 2 ). When patients re-evaluated the frequency of at least one of their adaptations at month 24, significant improvements in the frequency of adaptation were observed when compared with baseline values (Table 4 ). The pooled results from patients in the two trials showed significant reductions in frequency of adaptations as early as month 12 (P ¼ 0.001), with continued significant improvements in BSLA scores at 24 months in patients taking dutasteride as compared with those taking placebo (Po0.001).
Discussion
BPH is a progressive disease, especially among aging men, which involves benign growth of the prostate and can result in worsening of patients' symptoms. The majority of patients may seek treatment when symptoms become bothersome and result in deterioration of QOL. In some cases, nonpharmacologic therapy, such as surgical intervention, is necessary to alleviate symptoms. Nevertheless, it may not be preferred by many patients. 14 Medical therapy is an alternative that may delay or prevent the need for surgery. In this analysis, dutasteride produced significant improvements compared with placebo in the SPI, BSIA and BPWB questionnaires, with significant improvement in symptoms and QOL observed as early as month 12 from baseline. Patients experienced significant reductions in problems associated with urinary symptoms as measured by SPI, and these reductions correlated with decreased symptom scores when data from 4076 subjects from the two-year double-blind phase III trials were analyzed. In addition, each question from the AUA-SI positively correlated with the matching question from the SPI (Po0.0001). Dutasteride treatment resulted in significant improvement in all seven questions of both the AUA-SI 15 and SPI, including the nocturia scores. Although the overall numerical improvement was lower for nocturia than for the other questions, a treatment impact on this end point is important because the etiology of nocturia is often quite variable, and the effect of drug treatment is not well defined. Patient well-being improved on dutasteride as measured by BPWB. 16 As seen in the analysis of the BPWB questionnaire, dutasteride had the greatest effect on the desire for improvement in urinary problems, which is correlated with a patient's perceived degree of bother. 16 A reduction in frequency of lifestyle adaptations, as measured by the BLSA, was observed in this study. The efficacy of dutasteride in reducing LUTS allowed patients to return to normal activities of daily living with fewer lifestyle adaptations.
Consistent improvements in QOL measures were also seen in a study by O'Leary et al., 17 who previously assessed the effect of dutasteride on QOL using the BPH impact index questionnaire in patients randomized to treatment with dutasteride or placebo. The BPH impact index is a validated questionnaire 12 that measures the impact of symptoms that may affect a patient's health status and which serves as a practical approach to deciding whether medical or surgical intervention is necessary. Dutasteride use was associated with clinically and statistically significant improvements in BPH impact index scores.
Although two of the questionnaires (SPI and BSIA) used in the dutasteride studies were validated instruments, the BPWB and BSLA were not. Even though less is known about the clinical significance of the BPWB and BSLA measurements, the large sample size and the fact that all of the questionnaire results trended in the same direction (that is, patients reported improvements in symptoms) provide confidence that the effect of dutasteride on these various QOL measures is indeed real. Dutasteride improves quality of life measures MP O'Leary et al
Conclusions
Men who received dutasteride therapy to manage symptoms related to enlarged prostate experienced improvements in LUTS had improved QOL and were less likely to need to modify their behavior to alleviate occurrence or severity of bothersome symptoms. Because symptoms associated with enlarged prostate can have a tremendously negative impact on patients' QOL, clinicians should ensure that these issues are considered when diagnosing and treating men with LUTS resulting from prostatic enlargement.
